Seeking Alpha

otcmagic's  Instablog

Send Message
stock trader
My company:
My blog:
View otcmagic's Instablogs on:
  • StockTips Taking Over Where APS Left Off: A Look At Ecrypt Technologies Inc (OTCBB:ECRY)

    Ecrypt Technologies Inc (OTCBB:ECRY) was the latest pick from Godzilla penny stock promoter Stocktips who has gained fame in recent months for such promotions as TGRO, ALKM, WPWR and PGFY. TGRO is the one that put them on the map when it ran from pennies to $1.59 a share after they announced it as their pick.

    ECRY ran hard the day that StockTips announced as their pick hitting a high of $0.385 on record setting volume. This was followed by ECRY management issuing a press release distancing themselves from the promotion and saying they had no prior knowledge of it. This event tanked the price of ECRY and the stock hit a low of $0.16 before recovering and moving up from there.

    After hitting an all-time high of $0.59 ECRY collapsed back to its base at a dime marking the end of the StockTips promotion. Their disclaimer indicates that AC expects to receive $5,100,000 ($5.1 million) as a marketing budget for production and distribution of ECRY marketing material from 3rd party Laluna Services, Inc.

    Ecrypt Technologies Inc is at the forefront of data security, specializing in military-strength information security solutions for enterprise, government and military. Ecrypt empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.

    Statler was very vocal about his support for ECRY during the promotion stating at one point "Another quick note from me today…As we re-write the rule book - I want you to be made aware of something this morning. Today there might be LOTS of bashing of ECRY and StockTips… I don'twant you to allow it to hurt our momentum - so please read on!"

    I want to be very clear! This bashing only puts a ding in the momentum if you (our smart readers) allow it to do so… If you are steady, then these guys are not effective…If you see this for what it really is, then these guys stop with the nonsense, and its business as usual and we continue making the green! I was looking at one such article on seeking alpha today, and it was almost comical… First of all, it is evident that the article was written some time ago, and was most likely going to be prepared in advance and use it when the "TIME WAS RIGHT."

    In recent news ECRY said it has been made aware of a significant increase in the share price and trading volume of the Company's shares beginning Friday November 21, 2014.

    Since that time, Ecrypt has been subjected to an overly-aggressive promotional campaign promulgated by, which the Company believes is intended to create an emotionally-based "super-hype" about the explosive growth of the potential markets served by Ecrypt's products, by leveraging recent news reports about cyber security breaches of organizations. This promotional campaign is not endorsed or supported, either directly or indirectly, by the Company,

    The Company's management team has developed a detailed business plan and is focused on executing that plan. While management believes that it will be successful in implementing this plan, it does not in any way support the notion that the Company's product offerings (or its expected revenues) will yield "super" or hyper-growth sales at levels postulated by these overly aggressive and optimistic promotional campaigns.

    From the beginning management has distanced themselves from the $5.1 million Laluna StockTips promotion which is clearly over now and the emails from Statler have stopped long ago. Currently trading back where it started at a dime ECRY has no real fundamentals. The chances of ECRY recovering now are nil and investors only have to look at StockTips previous picks to get a better picture of where ECRY is headed.

    Please click here to find out more on ECRY and Stock Tips and what apsr projects for the stock. is quickly becoming the preeminent destination for up to date information on the hottest stocks in Penny stock World.

    Tags: ECRY, stocktips
    Dec 31 7:18 AM | Link | Comment!
  • Cellceutix Corp. (OTC: CTIX) Brilacidin Takes This To A Whole New Level

    Cellceutix Corp. (OTC: CTIX) is one penny stock that has got everyone's attention. Not only does CTIX continue to lead the OTCBB in volume and gains the Company is sitting on drugs in development that could potentially turn the multi-billion dollar drug-resistant cancers market upside down.

    Over the past 4 years CTIX has risen from pennies a share to recent highs near $5. Not only is the stock on fire with most investors suggesting this one goes way higher the stock continues to average over a million in daily dollar volume.

    OTCMAGIC has been covering CTIX since the stock was just over $0.50 per share back in early 2012 when it had run up from pennies, long before it went into multi dollar land and became one of the top traded stocks on the entire OTCBB exchange.

    CTIX lead drug Brilacidin continues to be the major catalyst in recent days after the FDA granted Qualified Infectious Disease Product (QIDP) status to Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI). Cellceutix is scheduled to meet with the FDA later this month on a planned Phase 3 trial evaluating the safety and efficacy of Brilacidin for ABSSSI.

    Cellceutix Corp (OTCMKTS:CTIX) is an emerging clinical stage biopharmaceutical company based in Beverly, Massachusetts. The Company develops innovative therapies in oncology, dermatology and antibiotic applications. The Company's chief scientific officer, Dr. Krishna Menon is a real whiz; he played key roles in developing two blockbuster cancer drugs; Gemzar and Alimta for Eli Lilly & Co.(NYSE:LLY) back in the late 90's.

    From OTCMAGIC 2012 Article on CTIX ''CTIX is quickly turning into the most exciting story in penny stocks; potentially sitting on the multi-billion dollar drug-resistant cancers market the Company's stock has been making a big move up off the $0.50 base where it sat for most of last summer.

    As anyone in the industry knows, regulating the p53 pathway has long been the holy grail of cancer research and big pharma has spent hundreds of millions of dollars researching ways to achieve this with no success thus far. It seems Kevetrin(NYSE:TM) has accomplished this; extensive preclinical research on Kevetrin shows the re-activation of p53 across a wide spectrum of cancer lines including colon, lung, breast and pancreatic cancers.

    If testing is successful, Mr. Ehrlich says the market potential for Kevetrin in treating drug-resistant cancers is worth $5 billion a year. Other cancers could easily represent an additional $5 billion annually, he adds.''

    CTIX flagship is Brilacidin, a new class of antibiotics called defensin-mimetics, which are modeled after host defense proteins. These are the "front line" of defense in the human immune system and mange suggest Brilacidin could rival Cubist's (NASDAQ:CBST) Daptomycin as the antibiotic of primary choice.

    On December 8 CTIX said ''that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation for Brilacidin as a new treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ahead of its meeting this month with Cellceutix regarding Cellceutix's planned Phase 3 trial of Brilacidin for ABSSSI. Brilacidin, the Company's lead drug in a new class of antibiotics called defensin-mimetics, completed a Phase 2b trial in September showing, amongst other things, a single dose of Brilacidin to be as effective in treatment of ABSSSI as a FDA-approved seven-day dosing regimen of daptomycin.

    The QIDP designation was established as part of the Generating Antibiotic Incentives Now (NASDAQ:GAIN) Act, passed by the U.S. Congress in July 2012, for the purpose of encouraging pharmaceutical companies to develop new antimicrobial drugs to treat serious and life-threatening infections. Receiving QIDP designation means that Brilacidin is now eligible for additional FDA incentives in the approval and marketing path, including Fast Track designation and Priority Review for development and a five-year extension of market exclusivity. ''

    CTIX investors know how lucky they are to have Mr. Ehrlich and Dr. Menon running the show. With a Brilacidin phase III trial in 2015 and a truly magnificent drug pipeline opening up the significant short position currently in CTIX has to be seriously concerned, especially after today.

    Currently CTIX has over $7 million in the treasury and is fully funded going forward. The stock is just now coming into the price range where they will be noticed by the primary players of biotechnology who could be all over this one. As I have been saying CTIX already looks and feels like a big board stock and is fast outgrowing the bb's.

    Please click here to find out more about Cellceutix Corp; CTIX and what OTCMAGIC projects for the stock. is quickly becoming the preeminent destination for up to date information on the hottest stocks in Penny stock World.

    Tags: CTIX, ctix, Brilacidin
    Dec 18 4:00 PM | Link | Comment!
  • GreenGro Technologies, Inc. (OTCMKTS:GRNH) Heats Up With The Sector

    GreenGro Technologies, Inc. (OTCMKTS:GRNH) has been highly volatile in recent weeks after Marijuana was legalized in Alaska, Oregon and Washington DC. Leading up to the ballots GRNH exploded skyward after seeing a recent low of $0.08. Investors still remember the spectacular run this one made earlier this year from subs to $1.20 per share.

    GRNH is a world class provider of eco-friendly green technologies with specific domain expertise in indoor and outdoor agricultural science systems serving both the consumer and commercial farming markets. It brings together community and commerce through the growth and distribution of healthy, nutritious foods and vital medicines backed by science and technology. Customers include restaurants, community gardens, small and large scale commercial clients. Greengro Technologies also provides design, construction and maintenance services to large grow and cultivation operations and collectives in the medical and recreational marijuana sectors.

    Besides Off the Grid Solar Systems from 300 watt to 20,000 watt Greengro has a number of products currently on the market including:

    Greenhouse Kits: The technology behind greenhouses is quite simple. Heat is trapped inside and is used to grow plants and vegetables. Using a greenhouse means the proper amount of humidity can be maintained, and this grows strong and healthy plants. It will also keep out bugs, animals and children, all of which can damage an outdoor garden.

    GRNH specializes in Vertical Systems which allows you to utilize as much space as possible. This means you can grow more plants than you could using a regular horizontal area. Because your plants will receive the maximum amount of light needed at all stages of development, your yields will increase.

    Whenever Marijuana stocks heat up GRNH is one to watch; the stock has proven to use it can run with the best of them exploding to well over $1 the last time the sector heated up.

    Please click here to find out more about GreenGro Technologies, Inc. GRNH and what OTCMAGIC projects for the stock. is quickly becoming the preeminent destination for up to date information on the hottest stocks in Penny stock World.

    Nov 14 7:11 AM | Link | Comment!
Full index of posts »
Latest Followers


More »

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.